EZH2 and ovarian carcinoma: Further delineation of EZH2’s role in the cisplatin resistance of ovarian cancer has shown that EZH2 inhibition does not induce apoptosis, but it can suppress the cisplatin-resistant human ovarian cancer cell line SKOV3/DDP autophagy and reverse resistance to cisplatin.